New drug E7090 tested in patients with advanced solid tumors
NCT ID NCT02275910
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested an experimental drug called E7090 in 40 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find the safest dose and check for early signs of effectiveness, especially in patients whose tumors have certain genetic changes in the FGF/FGFR pathway. The study focused on safety and tolerability, not on curing the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eisai Trial Site #1
Nagoya, Aichi-ken, Japan
-
Eisai Trial Site #1
Kashiwa, Chiba, Japan
-
Eisai Trial Site #1
Matsuyama, Ehime, Japan
-
Eisai Trial Site #1
Sapporo, Hokkaido, Japan
-
Eisai Trial Site #1
Amagasaki, Hyōgo, Japan
-
Eisai Trial Site #1
Tsukuba, Ibaraki, Japan
-
Eisai Trial Site #1
Kawasaki, Kanagawa, Japan
-
Eisai Trial Site #1
Yokohama, Kanagawa, Japan
-
Eisai Trial Site #1
Chuo-ku, Niigata, Japan
-
Eisai Trial Site #1
Kitaadachi, Saitama, Japan
-
Eisai Trial Site #1
Chuo-Ku, Tokyo, Japan
-
Eisai Trial Site #1
Koto-ku, Tokyo, Japan
-
Eisai Trial Site #1
Chiba, Japan
-
Eisai Trial Site #1
Fukuoka, Japan
-
Eisai Trial Site #1
Kyoto, Japan
-
Eisai Trial Site #1
Osaka, Japan
-
Eisai Trial Site #2
Osaka, Japan
-
Eisai Trial Site #3
Osaka, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.